Switching Agents in DME

Michael Javaheri, MD

Show Description +

Dr. Javaheri highlights real-world outcomes when patients with diabetic macular edema previously treated with another anti-VEGF agent switch to 8 mg aflibercept (Eylea HD, Regeneron).

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

switching

•

Diabetic macular edema, DME

•

Anti-VEGF

•

aflibercept

•

EYLEA HD

•

Eylea

•

Regeneron

Up Next

Name: Switching Agents in DME
Uploaded: 2025-08-06T18:58:55+00:00
Description: Dr. Javaheri highlights real-world outcomes when patients with diabetic macular edema previously treated with another anti-VEGF agent switch to 8 mg aflibercept (Eylea HD, Regeneron).

Treating Underrepresented Patients With DME

Andres Emanuelli, MD

Treating DR with OTX-TKI

Katherine E. Talcott, MD

An Oral Option for Stargardt Disease: New Data

Kenneth C. Fan, MD, MBA

Optogenetics for RP: 126-Week Data

David S. Liao, MD, PhD

ILM Flaps: 10 Years of Data

Zofia A. Nawrocka, MD, PhD

When to Treat with Pegcetacoplan

Roger A. Goldberg, MD, MBA

Treatment Burden: EYP-1901 Versus Aflibercept

Avni P. Finn, MD, MBA

Pharmacodynamics of ABBV-RGX-314

Robert L. Avery, MD

The PDS Versus Anti-VEGF Injections in the Fellow Eye

Jordan Graff, MD, FACS

UBX1325 For DME: Phase 2 Data

Dante Pieramici, MD

Back to All Videos

Switching Agents in DME

Michael Javaheri, MD

Dr. Javaheri highlights real-world outcomes when patients with diabetic macular edema previously treated with another anti-VEGF agent switch to 8 mg aflibercept (Eylea HD, Regeneron).

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

switching

•

Diabetic macular edema, DME

•

Anti-VEGF

•

aflibercept

•

EYLEA HD

•

Eylea

•

Regeneron

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Switching Agents in DME

Up Next

Switching Agents in DME

More From ASRS: 2025 Coverage